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CASE REPORT
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The induction of ovulation in women with hypogonado-
trophic hypogonadism requires follicle stimulating hor-
mone (FSH) for follicular growth and both FSH and
luteinizing hormone (LH) to induce optimal follicular
steroidogenesis. The development of human recombinant
FSH and LH means that individually tailored doses of both
hormones can be used with the aim of inducing unifollicular
ovulation. This report describes the use of recombinant
human FSH and LH for the induction of ovulation and
conception in the second cycle of treatment, and sub-
sequently a successfully completed pregnancy in a woman
with Kallmann's syndrome.
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Introduction
The development of molecular genetic technology has led to
the production of recombinant human follicle stimulating
hormone (r-hFSH) and luteinizing hormone (r-hLH). These
gonadotrophin preparations are >95% pure. Studies using
these highly purified gonadotrophins have shown that both
gonadotrophins are necessary for normal follicular function.
Although only FSH is required for follicular growth, LH is
necessary for adequate steroid production from developing
follicles as well as for follicular rupture following the LH
surge. A significant proportion of hypogonadotrophic patients
do not appear to have the minimum amounts of endogenous
LH required to achieve optimal follicular development and
steroidogenesis therapy with FSH alone, whether it is the
highly purified urinary FSH preparations or r-hFSH (Couzinet
et aL, 1989; Shoham et al., 1991). Therefore these patients
require the addition of LH for satisfactory follicular devel-
opment.
Case report
A 31 year old hypogonadotrophic woman presented to the
infertility clinic for investigation and treatment. She had
70
presented with incomplete pubertal development and primary
amenorrhoea at the age of 18 years. The clinical presentation
strongly suggested the diagnosis of Kallmann's syndrome, in
that she had hypogonadotrophic hypogonadism and anosmia.
There were no other midline defects. A computerized tomo-
graphy (CT) scan of the pituitary gland showed a pituitary
cyst, which was found consistently in subsequent CT scans.
Following diagnosis, the patient commenced oestrogen replace-
ment therapy. In June 1992, aged 31 years, she presented with
shortness of breath, swelling of the ankle and indigestion. She
was diagnosed as having sarcoidosis with lung and eye
involvement. She had no polyuria, polydipsia or other symp-
toms to suggest hypothalamic/pituitary sarcoid. She began
taking 30 mg/day prednisolone (Prednesol; Glaxo, UK) with
the good resolution of symptoms. At presentation, the patient
was using the oral contraceptive Logynon (ethinyl oestradiol
30-40 |ig/day and levonorgestrol 50-125 u.g/day) (Schering
Health, UK) and the dose of prednisolone had been decreased
to 3 mg/day.
A physical examination revealed mild obesity (body mass
index 25.4), normal breast development and axillary and pubic
hair (Tanner stage 5). Anosmia was confirmed. Visual fields
were full to confrontation.
By 1 month after stopping using Logynon, the serum FSH
concentration was 2.2 IU/1, the LH concentration was <1.0
IU/1 and the oestradiol concentration was 140 pmol/1. A
progestagen withdrawal test was negative. Prolactin and
thyroid-stimulating hormone concentrations were normal at
56.0 and 1.1 mIU/1 respectively. Haematological, renal and
liver function tests were all normal. A vaginal ultrasound scan
of her ovaries and uterus showed a small uterus (transverse
diameter 21 mm) and small inactive ovaries (right ovarian
volume 2.45 cm3, left ovarian volume 1.13 cm3).
A semen analysis of the patient's partner was normal.
Ovulation induction
The treatment protocol was established as part of a multicentre
trial to determine the effective dose of r-hLH to support
r-hFSH in ovulation induction in hypogonadotrophic women.
Ethical Committee approval was obtained from Parkside Health
Audiority, London, UK, and treatment commenced after written
informed consent was obtained from the patient. Treatment
was started with daily s.c. injections in the abdominal wall of
150 IU r-hFSH (Gonal-F®; Ares Serono, Aubonne, Switzer-
land) and 75 IU r-hLH (LHadi®, Ares Serono, Aubonne,
Switzerland). Ovarian follicular response and endometrial
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growth were monitored by ultrasound scans every 2-3 days.
FSH, LH and oestradiol concentrations were measured at each
visit. Two cycles of treatment were completed. After 9 days
of treatment in her first cycle she had developed a dominant
follicle (average diameter 17 mm) in the right ovary. There
were three smaller follicles (13-14 mm) in the left ovary.
There was an appropriate endometrial thickening of 11 mm
and a serum oestradiol concentration of 780 pmol/1. Human
chorionic gonadotrophin (HCG; 10 000 IU; Profasi®; Ares
Serono) was given i.m. on day 10. Luteal phase support of
2500 IU HCG i.m. was given 7 days after the first HCG
injection. The serum progesterone concentration measured
6 days after the first HCG injection was 20 nmol/1, followed
by a withdrawal bleed 6 days later.
The patient commenced a second cycle of treatment using
the same dose of r-hFSH (150 IU/day), but the dose of r-hLH
was increased to 225 IU/day. After 9 days of treatment, a single
dominant follicle (average diameter 17 mm) had developed in
the left ovary. The endometrium was 13 mm thick and the
oestradiol concentration was 760 pmol/1 on the day that 10 000
IU HCG were administered. Luteal phase support was given
as in the first cycle. The mid-luteal progesterone concentration
was 40 nmol/1. The patient conceived and an ultrasound scan
confirmed a viable singleton intrauterine pregnancy.
Apart from a few days of light perivitelline vaginal bleeding
in week 8, the pregnancy was uneventful until week 35. The
patient developed itchiness of the skin and then jaundice. Her
liver function tests were abnormal but ultrasound of the liver
and biliary tract was normal. A diagnosis of intrahepatic
cholestasis of pregnancy was made. Because of the increasing
derangement of liver function tests, labour was induced at 37
weeks. Delivery was by Caesarean section because of failure
to progress in labour. A healthy female infant weighing 3096 g
was delivered. There was a full resolution of liver function
post-partum.
Discussion
The successful induction of ovulation in women with hypo-
gonadotrophic hypogonadism and intact pituitary function has
been achieved with pulsatile gonadotrophin-releasing hormone
(GnRH) therapy or human menopausal gonadotrophin (HMG)
therapy. Pulsatile GnRH therapy has been the treatment of
choice because it restores the pulsatile release of both gonado-
trophins from the pituitary. This results in predominantly
unifollicular cycles and satisfactory pregnancy rates. The
treatment is associated with low rates of multiple pregnancy
and is not complicated by ovarian hyperstimulation syndrome
(Homburg et al., 1988; Balen et al., 1994).
However, for patients who do not respond adequately to
pulsatile GnRH or those with pituitary disease, HMG therapy
given by once daily injection has been the only alternative
treatment for ovulation induction. Urine-derived HMG prepara-
tions contain a fixed dose of FSH and LH. The use of
HMG is associated with an increased risk of multifollicular
development, with the potential complications of multiple
pregnancy and ovarian hyperstimulation syndrome.
The development of r-hLH used in addition to r-hFSH
provides another therapeutic option for patients who are
hypogonadotrophic. The successful induction of ovulation
using this regimen in a patient with hypogonadotrophic hypo-
gonadism was first reported in 1994 (Hull et al., 1994).
Because the two preparations are given separately, the dose
of each gonadotrophin can be tailored to the individual's
requirements and achieve the goal of unifollicular cycles. With
our patient, in the second cycle a higher dose of r-hLH (225
IU) was used and this was associated with the development
of a single dominant follicle. However, there was follicular
development in the first cycle of treatment using the lower
dose of 75 IU r-LH. It remains unclear as to whether the
higher dose of r-LH was the minimum effective dose required.
It is possible that the patient would have responded in the
second cycle by continuing with the same dose of r-LH. By
titration of both gonadotrophin doses for individual patients,
the potential complications seen with HMG therapy (i.e.
multiple pregnancy and ovarian hyperstimulation syndrome)
may be reduced with r-hLH and r-FSH therapy.
The patient's pregnancy was complicated by intrahepatic
cholestasis. This is a rare but well recognized benign complica-
tion of pregnancy. The condition, as with our patient, resolves
spontaneously after delivery. It is often reported to recur
in subsequent pregnancies but is not associated with the
development of chronic liver cell disease. It is unlikely that
the development of intrahepatic cholestasis was related to
gonadotrophin used to induce ovulation.
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